Alpha Thalassemia (HBA1 and HBA2) 7 Deletions
0051495
Ordering Recommendation
First-tier genetic test for confirmation of suspected alpha thalassemia.
Mnemonic
ALPHA THAL
Methodology
Polymerase Chain Reaction/Gel Electrophoresis
Performed
Mon, Thu
Reported
7-10 days  
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).  
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
  
Remarks
  
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Background Information for Alpha Thalassemia (HBA1 andHBA2) 7 Deletions:
Characteristics:
Alpha (+) thalassemia (silent carrier): Mutation of a single alpha2 globin gene (-α/αα); asymptomatic. Alpha (0) thalassemia (trait): Mutation of both alpha2 globin genes, or deletion of alpha1 and alpha2 globin genes in cis (-α/-α;--/αα); mild microcytic anemia possible. Hemoglobin H disease: Mutation of three alpha globin genes (--/-α); hemolysis with Heinz bodies, moderate anemia, and splenomegaly. Hb Bart Hydrops Fetalis Syndrome: Mutation of four alpha globin genes (--/--); lethal in fetal or early neonatal period.
Incidence:
Carrier frequency in Mediterranean (1:30-50), Middle Eastern, Southeast Asian (1:20), African, African-American (1:3).
Inheritance:
Autosomal recessive.
Cause:
Mutations in the alpha globin gene cluster; 95 percent are deletions.
Mutations Tested:
-α3.7,-α4.2,-(α)20.5,--SEA,--MED,--FIL,--THAI
Clinical Sensitivity:
Varies by ethnicity, may be as high as 90 percent.
Methodology:
Polymerase chain reaction and gel electrophoresis.
Analytical Sensitivity and Specificity:
Greater than 99 percent.
Limitations:
Rare alpha globin gene deletions, non-deletion mutations, gene duplications, and mutations of the regulatory region will not be detected. Diagnostic errors can occur due to rare sequence variations.





See Compliance Statement C: www.aruplab.com/CS
Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
 
Note
 
CPT Code(s)
81257
Components
Component Test Code*Component Chart Name
0051501Alpha Thalassemia, 7 Deletions
2001293Alpha Thalassemia, Specimen
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • alpha globin mutation deletions
  • HBA1, HBA2